Formulary Fireworks

In the wake of the high-profile showdown between Gilead and Express Scripts over the pricing of hepatitis-C drugs Sovaldi and Harvoni, the pharma/PBM balance of ...

Journal Ad Review: Back in the Mix

A few years ago medical publishers were approaching a cliff and the choices were simple: Evolve the business or fall over the edge. By having ...

Headliner: New Synta chief adds commercialization clout

Anne Whitaker, President and CEO, Synta Pharmaceuticals

Latest

Upward Move: Christine Petersen

Upward Move: Christine Petersen

Washington Insider: John Kamp

Washington Insider: John Kamp

The FDA must address its policies to accommodate the new medical and media environment

Back Talk: Eyes up, I'm talking to you!

Back Talk: Eyes up, I'm talking to you!

Your move? Lean in and make eye contact. Show that you care

PCORI explains how it will release comparative-effectiveness findings

PCORI explains how it will release comparative-effectiveness findings

The organization plans to publish a scientific and a lay abstract detailing study findings

Sanofi's new Lantus may not be the new Lantus

Sanofi's new Lantus may not be the new Lantus

Potential patients are expected to be newly diagnosed diabetes patients as opposed to Lantus switchers.

Drugmaker shifts sales model to keep pace with formulary decision making

Drugmaker shifts sales model to keep pace with formulary decision making

Some IDNs are centralizing decisionmaking at the corporate level and other hospitals are limiting on-site access to sales reps.

Concerns over Vyvanse marketing prior to approval: NYT

A report by the New York Times, citing a lack of an advisory committee for Vyvanse and illegal marketing lawsuits resolved last year, expressed concerns that the drug for binge-eating disorder will be overprescribed.

BI rare-disease awareness push slated for Saturday

Industry rare disease awareness efforts included a pipeline overview at Pfizer as well as BI's efforts to draw attention to IPF.

Lilly Lantus biosimilar to hit EU

The EU will have access to the new medication in May.

Agency Spotlight


 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters